UBS AM
AQST icon

UBS AM’s Aquestive Therapeutics AQST Stock Holding History

UBS AM’s Portfolio AQST Stock Details AQST Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.25K Hold
542
– – ﹤0.01% 3521
2026
Q1 		$2.25K Sell
542
-119,710
-100% -$486K ﹤0.01% 3574
2025
Q4 		$777K Buy
+120,252
New +$749K ﹤0.01% 2216

Other funds holding AQST

BCM
Bratton Capital Management Fort Worth, Texas $40.8M AUM 25.68% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.22B AUM 242.83% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
SCM
Sio Capital Management New York $604M AUM 96.57% 1-Year Est. Return

UBS AM's AQST Position: Q2 2026 in Review

UBS AM held its Aquestive Therapeutics (AQST) position steady in Q2 2026 at 542 shares worth $2.25K. The position accounts for ﹤0.01% of the portfolio, ranked #3521.

UBS AM first reported a position in AQST in Q4 2025 and has held it in 3 quarters since. The position peaked at $777K in Q4 2025. 185 funds tracked by Wall St. Rank hold AQST as of Q2 2026.

  • UBS AM held 542 shares of Aquestive Therapeutics worth $2.25K as of Q2 2026.
  • UBS AM left its Aquestive Therapeutics share count unchanged in Q2 2026.
  • Aquestive Therapeutics made up ﹤0.01% of UBS AM's portfolio in Q2 2026, its #3521 holding.
  • UBS AM first reported a position in Aquestive Therapeutics in Q4 2025 and has held it in 3 quarters since.
  • UBS AM's Aquestive Therapeutics position peaked at $777K in Q4 2025.
  • 185 funds tracked by Wall St. Rank held Aquestive Therapeutics as of Q2 2026.

Based on UBS AM's 13F filing for Q2 2026, filed 13 Aug 2026.